You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Drug use investigation in Japan

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

BENLYSTA® Special Drug Use Investigation

Recruiting
  • Systemic Lupus Erythematosus
  • Hiroshima, Japan
    GSK Investigational Site
Nov 24, 2022

Prostatic Tumors, Castration-Resistant Trial in Multiple Locations (Radium-223 dichloride (Xofigo, BAY 88-8223))

Active, not recruiting
  • Prostatic Neoplasms, Castration-Resistant
  • Radium-223 dichloride (Xofigo, BAY 88-8223)
  • Multiple Locations, Japan
    (unnamed)
Feb 2, 2023

Xarelto for Venous Thromboembolism (VTE)

Completed
  • Venous Thromboembolism
  • Rivaroxaban (Xarelto, BAY59-7939)
  • Multiple Locations, Japan
    Many locations
Oct 30, 2022

(DUI) of YazFlex for Endometriosis-associated Pelvic Pain and/or

Completed
  • Endometriosis and Dysmenorrhea
  • Multiple Locations, Japan
    Many locations
Nov 13, 2022

Ondexxya for Intravenous Injection 200mg Drug Use Result

Recruiting
  • Life Threatening Bleeding
  • Factor Xa Inhibitor
    • Tokyo, Japan
      Research Site
    Jul 7, 2022

    Drug Use Investigation of COMIRNATY Intramuscular Injection

    Active, not recruiting
    • COVID-19
    • BNT162b2
    • Tokyo, Japan
      PfizerLocal Country Office
    Jan 9, 2023

    Macular Degeneration (AMD) Post-marketing Surveillance in Japan

    Completed
    • Macular Degeneration
    • Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)
    • Multiple Locations, Japan
      (unnamed)
    Jan 9, 2023

    Prospective, Non-interventional, Multi-center Post-authorization

    Recruiting
    • Hypertension, Pulmonary
    • Riociguat (ADEMPAS, BAY63-2521)
    • Multiple Locations, Japan
      (unnamed)
    Jan 10, 2023

    Drug Vericiguat in Japanese People With Chronic Heart Failure

    Recruiting
    • Chronic Heart Failure
    • Vericiguat (Verquvo, BAY1021189)
    • Standard of care
    • Multiple Locations, Many Locations, Japan
      Japanese registries
    Feb 2, 2023

    Eylea in Babies Born Too Early Who HaveCondition of Eye Where

    Not yet recruiting
    • Retinopathy of Prematurity
    • +2 more
    • Aflibercept (Eylea, BAY86-5321)
    • Multiple Locations, Japan
      Many locations
    Jan 20, 2023

    Learn More About How Safe Darolutamide is Under Real-world

    Not yet recruiting
    • Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
    • No Intervention
    • Multiple Locations, Japan
      Many Locations
    Aug 24, 2023

    NTRK Gene Fusion - Positive Advanced or Recurrent Solid

    Recruiting
    • Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
    • Larotrectinib (Vitrakvi, BAY2757556)
    • Multiple Locations, Japan
      Many locations
    Jan 20, 2023

    Copaxone Subcutaneous Injection Syringe Special Drug Use-Result

    Recruiting
    • Multiple Sclerosis
    • Glatiramer acetate
    • Tokyo, Japan
      Takeda selected site
    Jan 12, 2022

    Teduglutide in Japanese People With Short Bowel Syndrome

    Recruiting
    • Short Bowel Syndrome
    • Tokyo, Japan
      Takeda Selected Site
    Oct 11, 2022

    Prospective, Non-interventional, Multi-center,

    Recruiting
    • Hypertension, Pulmonary
    • Riociguat (ADEMPAS, BAY63-2521)
    • Multiple Locations, Japan
      Many Locations
    Aug 17, 2022

    BOTOX® Drug Use Investigation (Spasmodic Dysphonia)

    Recruiting
    • Dysphonia
    • Tokyo, Japan
      GSK Investigational Site
    Oct 6, 2021

    Aflibercept Injection in Japanese Neovascular Glaucoma (NVG)

    Recruiting
    • Neovascular Glaucoma
    • Aflibercept (Eylea, BAY86-5321)
    • Multiple Locations, Japan
      Many locations
    Aug 17, 2022

    Regorafenib Post-marketing Surveillance in Japan

    Completed
    • Gastrointestinal Stromal Tumors
    • Regorafenib (Stivarga, BAY73-4506)
    • Multiple Locations, Japan
      (unnamed)
    Mar 21, 2022

    Prospective, Non-interventional, Post-authorization Safety Study

    Active, not recruiting
    • Thyroid Carcinoma
    • Sorafenib (Nexavar, BAY43-9006)
    • Multiple Locations, Japan
      (unnamed)
    Aug 18, 2022

    Leuprorelin Acetate Injection Kit 11.25 mg "All-Case

    Recruiting
    • Spinal and Bulbar Muscular Atrophy
    • Leuprorelin Acetate
    • Tokyo, Japan
      Takeda Selected Site
    Jan 12, 2022

    Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance

    Active, not recruiting
    • Relapsed or Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Lymphoma)
      • Aichi, Japan
      • +48 more
      Dec 7, 2022

      Zevalin Post-marketing Surveillance in Japan

      Completed
      • Non-Hodgkin's Lymphoma (NHL)
      • [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)
      • Multiple Locations, Japan
        (unnamed)
      Sep 30, 2021

      RELVAR® 100 ELLIPTA® Special Drug Use Investigation

      Completed
      • Pulmonary Disease, Chronic Obstructive
      • RELVAR 100 ELLIPTA
      • Hokkaido, Japan
      • +1 more
      Jul 26, 2021

      Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma

      Recruiting
      • Mesothelioma, Malignant
        • Shinjuku-ku, Tokyo, Japan
          Local Institution
        Apr 5, 2022

        Arnuity® Ellipta® Drug Use Investigation

        Completed
        • Asthma
        • Arnuity Ellipta
        • Hokkaido, Japan
        • +1 more
        Apr 22, 2021